Therapeutic Interchange for Insulin Detemir

The Division of Endocrinology and the Pharmacy and Therapeutics Committee has approved a therapeutic interchange for insulin detemir (Levemir®).

If Levemir is ordered inpatient via home medications or as a new order, the order will need to be converted to Lantus.  The conversion will be 1:1.  However, if a patient is pregnant, breast feeding, or has renal failure, the provider can contact their patient area care pharmacist or central pharmacy to order Levemir.

Providers will be presented with this message beginning April 1, 2019: